Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,769.20
(
-0.11%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.60
(
-1.86%
)
Bitcoin
70,615.42
(
-0.88%
)
News Focus
News Focus
Post# of 257261
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Double_Bagel post# 129303

Thursday, 11/03/2011 8:57:49 AM

Thursday, November 03, 2011 8:57:49 AM

Post# of 257261
SNY’s 3Q11 US sales of branded Lovenox were $184M*:

http://en.sanofi.com/Images/29017_20111103_Q3_2011_en.pdf

Since NVS reported $259M in 3Q11 sales of generic Lovenox, we now know that NVS had a 59% market share during 3Q11.

SNY’s PR at the above link confirms the launch of a Lovenox AG during October. The AG will be sold by SNY’s Winthrop business unit.

*€133M converted into dollars at the rate of $1.38, which approximates the average exchange rate during 3Q11.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now